DAWN WEBB: Open Payments
NPI 1912612441 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$925 in 59 payments from 14 companies in 2025. Trend: 2023 $926 · 2024 $932 · 2025 $925
Food & beverage: $925
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $228 |
| ABBVIE INC. | 14 | $189 |
| Novo Nordisk Inc | 6 | $106 |
| SHIELD THERAPEUTICS INC | 5 | $88 |
| GlaxoSmithKline, LLC. | 4 | $65 |
| Phathom Pharmaceuticals, Inc. | 6 | $62 |
| PFIZER INC. | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $22 |
Products named: FARXIGA, LINZESS, ACCRUFER, Ozempic, TRELEGY ELLIPTA, VOQUEZNA, UBRELVY, NURTEC ODT.
Industry payments across MS — which companies pay providers there.
